Gliomas
Malignant gliomas comprise a heterogeneous group of primary CNS tumors that are believed to originate from glial cells or their progenitor cells. Approximately 18 000 new cases are reported annually and these account for over 12 000 deaths in the USA (Jemal et al. 2006) . Although the majority of gliomas present in patients over the age of 55, gliomas are the most common solid cancer in children (Maher and Raffel 2004) . Unfortunately, tumor incidence has increased steadily over the past 30 years (Jemal et al. 2006) and the prognosis remains dismal (Azizi and Miyamoto 1998) . Effective therapies are lacking thus limiting treatment to radiation therapy and, where possible, surgery (Butowski et al. 2006) . Average survival following diagnosis can be up to 5 years but, more commonly, patients diagnosed with high-grade glioma succumb to the disease within just 6-12 months (Huncharek and Muscat 1998) .
Tumors generally form only from growth competent cells, hence, in the brain, primary tumors arise typically from glial cells and cells associated with the vasculature and meninges.
These tumors are collectively called gliomas (Kleihues et al., 1995) with the majority believed to originate from astrocytes, or their progenitor cells. Astrocytes retain the ability to divide throughout life and respond to acute injury and neurological disease through proliferation and the formation of scar tissue (Little and O'Callagha 2001) . These scarassociated astrocytes eventually divide and differentiate, leaving a tenacious tissue barrier. By contrast, glial-derived tumors fail to differentiate thereby maintaining unrestrained growth. Events that trigger malignant transformation of glial cells into gliomas are poorly understood. Genetic alterations in oncogenes [v-src, murine-double-minute-2 (MDM-2), cyclin-dependent kinase 4 (CDK-4), and epidermal growth factor receptor (EGFR)] and tumor suppressor genes (p53, p16, p15, and RB1) are common characteristics (Louis 1994; Von Deimling et al. 1995; Maher et al. 2001; Shapiro 2001) of the transformation of glial progenitor cells into tumorforming cells in mice (Holland et al. 1998) .
Gliomas share many fundamental biological alterations with other cancers. For example, they frequently show amplification of a constitutively active epidermal growth factor receptor that enhances tumor growth in the absence of exogenous growth factors (Tang et al. 1997) . Tumor suppressor genes such as p16 and p53 are frequently mutated (Von Deimling et al. 1995) . The induction of new blood vessels, or neovascularization, is a typical feature of many tumors and also characterizes high-grade gliomas (Plate and Risau 1995) . Despite these commonalities with other tumors, gliomas exhibit unique biological traits and have developed adaptations to support their unique biology. One of these physiological adaptations will be illustrated in this paper.
Physical constraints to tumor growth
Essentially all systemic tumors grow within soft tissue and are not physically limited in their growth. By contrast, primary brain tumors can only expand within the bony cavity of the cranium which ultimately limits tumor growth. Eightyfive percent of cranial volume is occupied by brain tissue with the remaining 15% filled with CSF. Ultimately, this space becomes insufficient for tumor expansion, necessitating the destruction and removal of normal brain tissue. Early in the disease progression tumors can be seen to push into the fluid spaces and often displace brain tissue, leading for example to a shift in midline structures as illustrated in Fig. 1 . It should be noted that the brain, like any body tissue, is incompressible given its cellular constituents are predominantly composed of water. However, text books and reviews frequently but incorrectly remark on the ability of growing tumors to compress the brain. One may refer more accurately to this phenomenon as a displacement of tissue into fluidfilled spaces, notably the ventricles. Figure 1 provides several examples illustrating how different sized tumors integrate into normal brain by displacing the surrounding brain tissue. In each instance, however, the characteristic gyrations of the cortical brain surface remains essentially unaltered and without evidence of compression. Hence, in each instance tumors have vacated the space into which they grew rather than simply pushing it aside. Surprisingly, little attention had been paid to the mechanism(s) whereby gliomas destroy normal brain tissue as they grow.
To fill this void, recent studies have examined this question and collectively suggest that glioma cells, at the growth margins of an expanding tumor, release the neurotransmitter glutamate into adjacent brain tissue at concentrations that are sufficient to cause neuronal cell death (Behrens et al. 2000; Chung et al. 2005) . Glutamate is the major excitatory neurotransmitter in the brain and is normally restricted to the synaptic and perisynaptic space of glutamateric synapses. Here, the transmitter binds to post-synaptic neuronal glutamate receptors and mediates fast signal transmission. In this restricted synaptic space glutamate rises to millimolar concentrations, yet its concentration in the extracellular space is typically very low, i.e. around 1 lM, to prevent the erroneous activation of extrasynaptic glutamate receptors. Prolonged activation of neuronal glutamate receptors, particularly NMDA receptors, can trigger a sustained influx of Ca 2+ which readily overwhelms intracellular Ca 2+ regulatory processes ultimately leading to Ca 2+ -mediated cell death (Choi 1988) . This process, introduced several decades ago (Olney et al. 1971) and termed excitotoxicity, is now believed to be a final common death pathway in many neurological diseases including acute trauma, ischemic stroke, amyotrophic lateral scelerosis (ALS) and Alzheimer's disease (Choi 1988; Lipton and Rosenberg 1994) . Because of the vulnerability of the brain to excessive glutamate, protective mechanisms evolved in the form of Na + -dependent transport systems that maintain extracellular glutamate at harmless micromolar concentrations (Danbolt 2001) . These transporters are predominantly expressed on astrocytes (Danbolt 2001) and include the excitatory amino acid transporters 1 and 2 (EAAT1 and 2) formerly known as glial amino acid transporter and glutamate transporter-1 (Danbolt 2001) . Their role in neuroprotection has been conclusively demonstrated through knockout studies in which a loss of glutamate uptake by glial cells resulted in widespread neurodegeneration and lethal epilepsy (Rothstein et al. 1996; Tanaka et al. 1997 ).
Glioma cells release glutamate and kill peritumoral neurons by an excitoxic mechanism
The first evidence that glial-derived tumor cells release glutamate rather than remove it from the extracellular space came from a transport study that directly compared normal and malignant glial cells . This study used glioma cell lines established from patients as well as acute patient biopsy tissues showing a lack of expression of the most prominent astrocytic glutamate transporter EAAT2 (glutamate transporter-1), a finding that was recently corroborated by microarray analysis of glioma tissues (de Groot et al. 2005) . Staining of tissue biopsies with EAAT2 antibodies clearly demarcates the tumor boundaries where non-malignant astrocytes prominently express EAAT2, yet gliomas lack its expression (Fig. 2a) . During embryonic development, astrocytes also express EAAT1 (glial amino acid transporter) and many cultured astrocytes maintain expression of this related member of the EAAT family of Na + -dependent transporters (Ullensvang et al. 1997) . Interestingly, EAAT1 is found mislocalized to the nucleus of gliomas in brain biopsies from glioma patients ). This failure to express functional glutamate transporters results in significant reductions in glutamate uptake, representing at best 5% of that observed in normal astrocytes. More surprising was the converse finding that these tumor cells actually release glutamate. In the presence of extracellular cystine, a monolayer of cultured glioma cells is able to raise extracellular glutamate concentrations in a culture flask 500-fold within just a few hours (Fig. 2b) . When hippocampal or cortical neurons are placed in the vicinity of gliomas, neurons undergo NMDA-dependent excitotoxic cell death ( Fig. 2c ) . Further molecular, pharmacological, and ion-dependence studies ultimately led to the identification of system X c , a cystine-glutamate exchanger , as the principal protein responsible for glutamate release from glioma cells . Once released into the peritumoral space Takano et al. 2001) , glutamate causes widespread excitotoxic death of peritumoral neurons . We and others have proposed that this form of excitotoxic neuronal cell death allows the tumor to expand into the vacated space (Takano et al. 2001) . In a more recent study discussed below (Lyons et al. 2007) , we suggest that the released glutamate may also serve as a trophic factor promoting glioma cell invasion and the formation of tumor metastasis. It is worth mentioning that glutamate has been shown to more broadly influence the biology of malignant and non-malignant glial cells. For example, activation of metabotropic, G-protein coupled glutamate receptors stimulates DNA synthesis and activates mitogen-activated protein kinases in astrocytes (Schinkmann et al. 2000) . In glioma cells, Ca 2+ influx through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors stimulates cell proliferation through phosphorylation of AKT (Ishiuchi et al. 2007) . Moreover, in areas of tissue inflammation, glutamate activates microglial cells (Biber et al. 2007) which would be expected to contribute to the inflammatory milieu around a growing tumor. These additional effects of glutamate will undoubtedly contribute to the evolution of the disease and warrant further study. Glutamate release is mediated by the cystineglutamate antiporter system X c As indicated above, the Na + independent release of glutamate occurs via the system X c cystine glutamate antiporter. This electroneutral, Na + independent amino acid transporter (Sato et al. 1999 ) exchanges cystine for glutamate (GLU) and is up-regulated under conditions of oxidative stress (Kim et al. 2001) . Molecular cloning identified this transporter as a dimeric protein composed of a catalytic (xCT) and a regulator subunit (4F2hc). The transporter is found in both normal and malignant human brain by western blot (Fig. 3a) but appears universally up-regulated in glioma tissues. Indeed, being responsible for the cellular synthesis of GSH and hence cellular redox regulation, it is not surprising that system X c is regulated by oxidative stress and nitric oxide (Dun et al. 2006) presumably via the activation of transcription factor NF-E2-related factor which regulate xCT transcription via binding to an antioxidant response element (Sun et al. 2005) . In normal glia cells, system X c does not account for a significant glutamate release as any glutamate release through the antiporter in conjunction with cystine uptake is quickly removed through reuptake by EAAT2 which has a much higher capacity for Glu transport and a high affinity of extracellular Glu. This concept is schematized in Fig. 3c . In turn, the lack of reuptake mechanisms in gliomas explains a progressive accumulation of glutamate in the vicinity of the tumor which inflicts excitotoxic injury on adjacent neurons as schematized in Fig. 3d .
Although the initial studies investigating glutamate release from gliomas were based on cultured cells and animal models bearing experimental gliomas (Takano et al. 2001) , these findings have now been corroborated in patients with malignant gliomas. One of these studies used microdialysis (Roslin et al. 2003) to directly sample peritumoral fluids in fully ambulatory glioma patients; the other used spectroscopic magnetic resonance imaging to detect glutamate (Rijpkema et al. 2003) . Both studies confirm significant increases in peritumoral glutamate in all glioma patients examined. This finding explains why up to 80% of all glioma patients present with peritumoral seizures, many of them during early, often less malignant stages of the disease (Oberndorfer et al. 2002) . The glutamate released from gliomas would be expected to activate neuronal glutamate receptors that underlie such seizures in the vicinity of the tumor and likely precede excitotoxic cell death.
Glutamate release is an obligatory byproduct of GSH synthesis
While the excitotoxic elimination of peritumoral neurons may be of potential benefit to the growing tumor, it is unlikely that this pathway evolved with the primary purpose to kill neurons. Instead, it is more likely that glutamate release occurs as an obligatory byproduct of cystine uptake by these tumor cells (Fig. 3b and e) . Cystine is an essential precursor for the biosynthesis of the cellular antioxidant GSH, a tripeptide of glutamate, cysteine (the reduced form of cystine) and glycine. The supply of cysteine is essential for GSH biosynthesis making cellular uptake of cystine rate limiting for overall GSH production. GSH levels are increased in gliomas and may make these tumors more resistant to oxidative stress and exposure to certain chemotherapeutic drugs (Iida et al. 1997 ). Importantly, radiation damage which is mediated by hydroxyl radicals (Knuutila 1984) is also reduced by GSH (Simone et al. 1983 ) and hence elevated GSH levels confer radiation resistance to tumors (Mitchell et al. 1989) .
Therapeutic targeting of system X c -mediated glutamate release to contain tumor growth
If system X c represent the major uptake pathway for cystine and release pathway for glutamate, one would expect that its inhibition should interfere with tumor growth in two ways. First, limiting cystine uptake should starve the cells of GSH making the cells more susceptible to oxidative challenges such as radiation treatment. Second, the inhibition of glutamate release should curtail seizures and may contain tumor expansion. To examine these possibilities, two pharmacological inhibitors have been identified as suitable drug candidates. These are S-4CPG, a phenylgycin derivative and agonist for metabotrobic glutamate receptors , and sulfasalazine (Chung et al. 2005) , a drug clinically used to treat chronic inflammatory bowl disease. Both drugs inhibit cystine uptake and glutamate release at 100-250 lM drug concentration (Chung et al. 2005) . Importantly, a 24 h exposure to either drug causes the near complete depletion of intracellular GSH (Fig. 4a ) and in turn leads to growth arrest of gliomas (Chung et al. 2005) . The growth retarding effect is entirely because of a depletion of GSH as cells can be rescued from growth arrest with a membrane permeant, GSH ester. As sulfasalazine is a Food and Drug Administration approved drug that can be readily given to patients, pre-clinical studies examining its growth retarding effect have mainly focused on this compound. Specifically, severe combined immunodeficient (scid) mice with implanted human gliomas were treated twice daily by i.p. injection of sulfasalazine for up to 10 weeks and tumor response was monitored by bioluminescence imaging as well as quantitative stereology on histopathological specimens (Chung et al. 2005) . As illustrated in Fig. 4 , sulfasalazine reduced tumor volume by 60-80%. These studies were carried out with sulfasalazine doses comparable with those taken by patients suffering from Crohn's disease for which an adequate safety profile is well established. These findings suggest a rapid path to clinical translation and the author's home institution is in the process of initiating a clinical study to evaluate oral sulfasalazine in a phase I clinical study for patients with malignant glioma. As a second approach, clinical studies may seek to inhibit the glutamate receptors targeted on neurons and glioma cells, with neuronal NMDA receptor being the primary candidate. Although NMDA-receptor antagonists have had mixed results in the treatment of stroke (Lipton 2004) , they may represent a viable treatment modality in advanced stages of brain cancer warranting further study. Use-dependent glutamate receptor antagonists such as Amantadine have been explored with promising indication toward reducing aberrant activation of neuronal NMDA receptors in clinical studies for stroke (Lipton 2004 ), Parkinson's disease (Verhagen et al. 1998 ) and, based on animal studies (Takano et al. 2001) , may indeed represent a viable treatment strategy for gliomas.
Glutamate stimulates glioma metastasis
As discussed above, the unusual ability of glioma cells to invade the normal brain presents a huge clinical challenge. Consequently, a great deal of research has been devoted toward gaining a better understanding of the underlying biology. This research has identified a multitude of factors and adaptations which include a preference for certain substrate for cell migration (Demuth and Berens 2004) . Indeed, invading gliomas can synthesize their own unique extracellular matrix as they invade (Zamecnik 2005) . These cells interact with extracellular matrix through integrin receptors (Gladson 1999) , also involved in the dynamic attachment/detachment of focal adhesion sites. Some of these dynamic changes appear to correlate with changes in intracellular Ca 2+ (Manning et al. 2000) and intracellular Ca 2+ oscillations frequently correlate with cell migration (Maghazachi 2000) . These have also been observed in migratory glioma cells (Bordey et al. 2000) . Ca 2+ oscillations can be triggered by a number of extracellular ligands including growth factors (Bryant et al. 2004) , lysophosphatidic acid (Manning et al. 2000) and neurotransmitters such as acetylcholine (Komuro and Rakic 1996) and glutamate (Kim et al. 1994) . Glutamate is of particular interest in this context as studies on cerebellar granule cells suggest an absolute requirement for glutamate-mediated Ca 2+ oscillations in neuronal migration (Komuro and Rakic 1996) . Here, the activation of NMDA receptor causes the transient influx of Ca 2+ which in turn regulates the rate and velocity of granule cell migration (Komuro and Rakic 1998) . Although glioma cells express receptors for glutamate, unlike granule cells, they do not express NMDA receptor. Instead, they express a subclass of AMPA receptors which is Ca 2+ permeable (Lyons et al. 2007) . These receptors lack the GluR2 subunit which is required to prevent Ca 2+ permeation (Hollmann et al. 1991) resulting in Ca 2+ permeable AMPA receptor. To demonstrate a role for these receptors in glioma migration, Ishiuchi et al. (2002) transfected the GluR2 subunit into glioma cells using a viral transfection system. This rendered glioma cells unable to respond to glutamate with Ca 2+ oscillations and upon implantation into a host animal brain these glioma cells failed to invade. Hence glutamate acts to promote cell migration through activating Ca 2+ entry. Although glioma cells utilize a different receptor system, they appear to recapitulate the same underlying biology that is observed in early development in neuronal migration. Interestingly, oligodendrocytes progenitor cells which may be a non-malignant precursor for gliomas (Dai et al. 2001) have recently been shown to engage AMPAreceptor activation as they migrate. Here, glutamate binding to AMPA receptor causes the formation of an alphav integrin/proteolipid protein (PLP)/neurotransmitter receptor protein complex that reduces binding to the extracellular matrix thereby enhancing oligodendrocytes progenitor cells migration (Gudz et al. 2006) .
In the case of neurons, the source for glutamate acting in a migration-promoting way (i.e. as a 'motogen') is unknown. In gliomas, glutamate is release from the tumor cells themselves and may function in a dual capacity. It clears the way for the tumor growth, and it may activate AMPA receptors on the same or neighboring glioma cells to initiate the necessary Ca 2+ signal for promoting cell motility and invasion. Indeed, recent studies support this hypothesis (Lyons et al. 2007) , suggesting that glioma cells respond preferentially to glutamate released via system X c . As illustrated in Fig. 5a , inhibition of glutamate release via system X c using sulfasalazine inhibits Ca 2+ responses and also reduces Transwell glioma migration (Fig. 5b) . The fact that migration could be restored when glutamate was added back into the system in the continued presence of the system X c inhibitor sulfasalazine (Fig. 5b ) supports a motogenic function for glutamate. Moreover, the inhibition of AMPA receptors with Jolo-Tx, a specific inhibitor of Ca 2+ -permeable AMPA receptors, prevented migration stimulated by glutamate clearly implicating this receptor as essential in glioma invasion. Together this data supports the hypothesis that glutamate serves a dual purpose in glioma biology: (i) by acting as an excitotoxin, it clears space for tumor expansion thereby promoting tumor growth; and (ii) by acting as a motogen, it enhances the motility and consequently promotes tumor invasion. Glioma cells often display chain migration whereby many cells follow a lone leader (Fig. 5c) . It is conceivable that the leading cell recruits its followers through the targeted (paracrine) release of glutamate as it migrates. These findings have important therapeutic implications as inhibition of either AMPA receptor on gliomas or the autocrine glutamate from glioma via system X c should prevent glioma metastasis. As alluded to before, glutamate receptor antagonists may represent a viable approach to reduce glioma invasion and warrant further study. The inhibition of glutamate release from gliomas using sulfasalazine has not been previously considered as a glioma therapeutic but now appears to be a plausible strategy to curtail glioma invasion.
Epilogue
As these examples illustrate, glioma cells utilize transporters and transmitter receptors in ways to enhance their unique biology. They appear to co-opt the function of these proteins which are normally involved in cell-cell signaling or to maintain a homeostatic brain environment. They use them to enhance their own ability to grow and invade normal brain. Unexpectedly, amino acid transporters may be considered viable and much needed therapeutic targets for glioma and possibly many other cancers.
